Since its founding, Akums Drugs and Pharmaceuticals has developed over 4,146 commercial formulations across more than 60 different dosage forms. In FY24, the company manufactured pharmaceutical products for 26 of the top 30 companies in India in terms of sales.
Akums operates 10 manufacturing facilities with a combined annual production capacity of 49.23 billion units as of March 31, 2024.
As of March 31, 2024, Akums Drugs’ CDMO business served a client base of 1,524 Indian and multinational companies, up from 1,386 on March 31, 2022. This group of clients includes pharmaceuticals, nutraceuticals, cosmo-derma, and wellness companies, as well as e-commerce businesses, healthcare providers, and various government entities at both the central and state levels.
Akums Drugs and Pharmaceuticals operates four research and development (R&D) units, two of which are approved by the Department of Scientific and Industrial Research, under the Ministry of Science and Technology, Government of India.
As of March 31, 2024, Akums Drugs and Pharmaceuticals exported branded pharmaceutical formulations to 65 countries.
As of March 31, 2024, Akums Drugs and Pharmaceuticals' CDMO business clients include names such as Alembic Pharmaceuticals, Alkem Laboratories, Blue Cross Laboratories, Cipla, Dabur India, Dr. Reddy’s Laboratories, Hetero Healthcare, Ipca Laboratories, Mankind Pharma, MedPlus Health Services, Micro Labs, Mylan Pharmaceuticals, Natco Pharma, Sun Pharmaceutical, UCB, and Amishi Consumer Technologies (The Mom’s Co), among others.
Akums Drugs and Pharmaceuticals' operations and research facilities are primarily located in Haridwar, Uttarakhand. Any change in the business environment in the state could adversely impact the company’s operations.
The company relies heavily on a relatively small group of clients for a substantial share of its revenue. In FY22, FY23, and FY24, its top 10 clients contributed 41.27% (Rs 1,098.27 crore), 38.92% (Rs 1,059.75 crore), and 39.31% (Rs 1,284.11 crore) to the revenue from operations, respectively. A loss of any of these major clients could harm Akums' business.
Akums Drugs, some of its promoters, subsidiaries, and directors are involved in various legal proceedings. Any adverse judgments in these cases could hurt the company’s business.
In FY22, the company reported a financial loss of Rs 250.87 crore.
As of March 31, 2024, the total indebtedness of the company reached Rs 493.89 crore. Any inability to service or repay these debts on time could negatively impact its business.